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Leishmania speciﬁc CD4 T cells release IFN-
that limits parasite replication in patients with
visceral leishmaniasis
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Background: An immunological feature of VL patients is the
inability of PBMC to respond to leishmanial antigen. But unex-
pectedly, it was recently found that Leishmania speciﬁc IFN-,
can readily be detected when a whole blood stimulation assay is
used. We explored the conditions that permit whole blood cells to
respond to antigen stimulation, and clarify the biological role of the
IFN-.
Methods & Materials: Whole blood and PBMC from VL patients
were used anddifferent cytokines weremeasured by ELISA. To test
the role of complements, antibodies or other proteins present in
plasma on SLA induced IFN- production, we replaced the plasma
withheat inactivated FBS.Magnetic beads andcolumnbaseddeple-
tion method were used to ﬁnd the cellular sources of SLA induced
IFN- production and further validated by intracellular cytokine
staining. We employed an ex-vivo assay using splenic aspirate (SA)
cells of active VL cases to assess the effect of IFN- blockade on par-
asite growth and pathology. Viable amastigote count and cytokine
levels in culture supernatantswere used as a read-out for the assay.
Results: CD4+T cells are main source of leishmania speciﬁc
IFN- production in VL patients. Complement, antibodies and RBC
do not play any signiﬁcant role in the IFN- responses. However,
removal of CD15+or CD56+ cells reduced IFN production, sug-
gesting that neutrophils andNK cells or other cells expressing these
markers, contribute to the response in Whole Blood. Blockade of
IFN-, increases amastigote numbers in SA cultures which can be
argued to support their role in promoting immunity in patients
with active disease.
Conclusion: Most patients with VL have antigen speciﬁc cells
capable of secreting IFN- both in blood and spleen. Endogenous
IFN-plays role in limitingparasite growthandcouldbeconsidered
as apotential target in immunebased therapyaloneor as anadjunct
to reduce the dose and length of treatment.
http://dx.doi.org/10.1016/j.ijid.2014.03.752
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Amine modiﬁed graphene mediated drug
delivery of Amphotericin B for the treatment of
visceral leishmaniasis
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Background: We evaluated a novel formulation of Ampho-
tericin B (AmB) conjugated to amine-modiﬁed graphene (f-Gr) for
safety and efﬁcacy over conventional AmB.
Methods & Materials: The f-Gr was prepared in a gentle
one step process of non covalent (amine) functionalization with
the help of amino acid L-cysteine. Non-covalent functionaliza-
tion of graphene with - interactions works as the binding
force between graphene and the ligand. This amine functional-
ized graphene sheet is further conjugated to AmB. The conjugate
(f-Gr-AmB) was characterized by FTIR, SEM, TEM and Raman spec-
troscopy that established successful attachment of AmB to f-Gr.
Cytoxicity of aminemodiﬁed graphene Amphotericin B (f-Gr-AmB)
is assessed invitro against J774A.1macrophage cell lines and invivo
in Swiss mice. Antileishmanial activity of f-Gr-AmB is tested in vivo
in hamsters and against J774A.1 macrophage cell lines in vitro.
Results: FTIR, SEM, TEM and Raman spectroscopy showed suc-
cessful attachment of AmB to f-Gr. The f-Gr-AmB was found to
exhibit lesser cytotoxity towards J774A.1 cells than AmB, and
did not induce any hepatic or renal toxicity in Swiss albino
mice. In vitro antileishmanial assay in J774A.1 showed signiﬁcantly
enhanced efﬁcacy of f-Gr-AmB over AmB. Furthermore, Percentage
Inhibition of amastigote replication in hamster model of VL was
signiﬁcantly higher in f-Gr-AmB treated group (87.8%) compared to
AmB (70.4%).
Conclusion: These results suggest that f-Gr-AmB could be a safe
and effective alternative to conventional AmB in the treatment of
VL.
http://dx.doi.org/10.1016/j.ijid.2014.03.753
